Using gene therapy to treat genetic eye disease aniridia
In 2020, Fighting Blindness Canada awarded Dr. Elizabeth Simpson at the University of British Columbia a research grant of $297,000 to support the development of a potential gene therapy for the inherited…
Canadians Begin Receiving Sight-Saving Gene Therapy.
Over the past few years, we have been sharing about the excitement and challenges of bringing the first gene therapy for an eye disease, Luxturna, to Canada. We continue the journey, sharing…
Wait Continues for Sight-Saving Gene Therapy
Despite being approved by Health Canada in October 2020, more than 40 families across the country continue to wait for a decision on public funding of Luxturna, a sight-saving gene therapy. Luxturna…
BREAKING NEWS … Canadians one step closer to Luxturna Gene Therapy Access
Fighting Blindness Canada is excited to announce that Canadians are one step closer to being able to access voretigene neparvovec (Luxturna), the first gene therapy for an inherited retinal disease. As of…
Gene therapy Luxturna recommended for public health care coverage
Another hurdle in the process to bring the gene therapy Luxturna to Canadians has been cleared! In the last few weeks, the Canadian Agency for Drugs and Technologies in Health (CADTH) and…
THE FUTURE IS BRIGHT: HEALTH CANADA APPROVES FIRST SIGHT-RESTORING GENE THERAPY FOR INHERITED EYE DISEASES
On October 14, 2020, Health Canada announced their approval of the first targeted gene-therapy treatment voretigene neparvovec (Brand name: Luxturna) for an inherited retinal disease (IRD). This announcement is the first targeted…
Join the Fight!
Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our e-newsletter that lands in inboxes the beginning of each month.